|
rs1042838
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Patients carrying rs1042838 G/T, rs590688 C/C, and rs10895068 G/A genotypes had higher risk of breast cancer, while carriage of rs3740753 G/G genotype was associated with marginal reduction in breast cancer risk.
|
29302853 |
2020 |
|
rs1042838
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We did not observe an association between potential functional genetic polymorphisms in the estrogen pathway, SHBG rs6259, ESR1 rs2234693, CYP19 rs10046 and rs4775936, and UGT1A1 rs8175347, or the progesterone pathway, PGR rs1042838, with the risk of breast cancer.
|
23935996 |
2013 |
|
rs1042838
|
|
|
0.060 |
GeneticVariation |
BEFREE |
We conclude that the leucine allele of the V660L SNP may be associated with a small increase in breast cancer risk, while the other four PGR SNPs, +44C/T (rs518162), +331G/A (rs10895068), H770H (rs1042839) and Q886Q (rs500760), do not substantially increase breast cancer risk.
|
17592773 |
2008 |
|
rs1042838
|
|
|
0.060 |
GeneticVariation |
BEFREE |
After both stages, only one SNP was significantly associated with an increased risk of breast cancer - the PGR-12 (rs1042638) V660L valine to leucine polymorphism [VL heterozygotes (odds ratio, 1.13; 95% confidence interval, 1.03-1.24) and the LL homozygotes (odds ratio, 1.30; 95% confidence interval, 0.98-1.73), P(het) = 0.008, P(trend) = 0.002].
|
16614108 |
2006 |
|
rs1042838
|
|
|
0.060 |
GeneticVariation |
BEFREE |
Overall, our study does not support an association between the Val660-->Leu PROGINS polymorphism and breast cancer risk.
|
15535845 |
2004 |
|
rs1042838
|
|
|
0.060 |
GeneticVariation |
BEFREE |
The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian women.
|
12010857 |
2002 |